Exact Sciences Co. (NASDAQ:EXAS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Exact Sciences Co. (NASDAQ:EXAS) has received an average rating of “Moderate Buy” from the thirteen research firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $93.07.

A number of equities research analysts have recently issued reports on EXAS shares. Citigroup dropped their target price on shares of Exact Sciences from $100.00 to $80.00 and set a “buy” rating on the stock in a report on Thursday, May 9th. Canaccord Genuity Group dropped their price objective on Exact Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Thursday, May 9th. TheStreet downgraded Exact Sciences from a “c-” rating to a “d+” rating in a research note on Monday, February 26th. BTIG Research decreased their target price on Exact Sciences from $85.00 to $80.00 and set a “buy” rating on the stock in a report on Thursday, May 9th. Finally, Jefferies Financial Group started coverage on Exact Sciences in a report on Monday, June 3rd. They set a “buy” rating and a $75.00 price target for the company.

Exact Sciences Stock Up 1.9 %

Shares of EXAS stock opened at $44.85 on Friday. The firm’s fifty day moving average price is $52.46 and its two-hundred day moving average price is $61.01. Exact Sciences has a 1 year low of $41.08 and a 1 year high of $100.77. The company has a current ratio of 1.64, a quick ratio of 1.45 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $8.28 billion, a P/E ratio of -33.98 and a beta of 1.26.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Wednesday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.50). The business had revenue of $637.52 million for the quarter, compared to analyst estimates of $624.95 million. Exact Sciences had a negative return on equity of 7.12% and a negative net margin of 9.48%. On average, equities analysts predict that Exact Sciences will post -1.15 EPS for the current fiscal year.

Insider Buying and Selling at Exact Sciences

In other news, EVP Sarah Condella sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $70.00, for a total transaction of $140,000.00. Following the transaction, the executive vice president now directly owns 71,787 shares of the company’s stock, valued at $5,025,090. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, EVP Sarah Condella sold 2,000 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $70.00, for a total transaction of $140,000.00. Following the sale, the executive vice president now directly owns 71,787 shares of the company’s stock, valued at approximately $5,025,090. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Kevin T. Conroy sold 1,155 shares of the business’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $60.15, for a total value of $69,473.25. Following the completion of the transaction, the chief executive officer now directly owns 1,156,191 shares of the company’s stock, valued at approximately $69,544,888.65. The disclosure for this sale can be found here. Insiders sold 5,498 shares of company stock valued at $370,105 in the last quarter. Company insiders own 1.36% of the company’s stock.

Institutional Trading of Exact Sciences

Institutional investors and hedge funds have recently made changes to their positions in the company. Wolff Wiese Magana LLC raised its position in Exact Sciences by 459.5% during the fourth quarter. Wolff Wiese Magana LLC now owns 414 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 340 shares in the last quarter. Benjamin F. Edwards & Company Inc. boosted its holdings in shares of Exact Sciences by 65.6% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 452 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 179 shares in the last quarter. Able Wealth Management LLC bought a new position in shares of Exact Sciences in the 4th quarter valued at $45,000. EverSource Wealth Advisors LLC raised its holdings in shares of Exact Sciences by 92.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 708 shares of the medical research company’s stock worth $49,000 after buying an additional 340 shares in the last quarter. Finally, Valley National Advisers Inc. lifted its position in shares of Exact Sciences by 29.5% during the 3rd quarter. Valley National Advisers Inc. now owns 773 shares of the medical research company’s stock worth $53,000 after buying an additional 176 shares during the last quarter. Institutional investors own 88.82% of the company’s stock.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.